GLP-1 receptor agonists, such as Ozempic, Wegovy, Mounjaro, and Zepbound, have been associated with several legal actions due to alleged severe side effects and issues related to compounded versions of these medications.
Product Liability Lawsuits:
Patients have filed lawsuits against manufacturers like Novo Nordisk and Eli Lilly, alleging that the use of GLP-1 drugs led to serious gastrointestinal issues, including gastroparesis (stomach paralysis), intestinal blockages, and gallbladder damage. These lawsuits claim that the companies failed to provide adequate warnings about these potential risks. In February 2024, the Judicial Panel on Multidistrict Litigation (JPML) consolidated 55 such lawsuits into a multidistrict litigation (MDL 3094) to streamline pretrial proceedings. By December 2024, the number of pending lawsuits in this MDL had increased to 1,300.
Compounded Medication Disputes:
Compounding pharmacies have been producing and selling cheaper versions of GLP-1 drugs, particularly during periods when the original medications were listed on the FDA’s drug shortage list. Eli Lilly, the manufacturer of Mounjaro and Zepbound, has taken legal action against these pharmacies, sending cease-and-desist letters and seeking to join lawsuits to protect its patents and market share. The FDA’s decisions regarding drug shortages significantly impact the legality of these compounded versions. For instance, in late 2024, the FDA declared certain GLP-1 drugs as “available,” ending their shortage status and thereby restricting compounding pharmacies from legally preparing generic versions.
Regulatory Scrutiny:
The FDA has issued warnings about the use of unapproved compounded versions of GLP-1 drugs for weight loss, emphasizing that these unapproved versions have not undergone the agency’s review for safety, effectiveness, and quality. This regulatory stance has led to increased legal scrutiny and actions against entities involved in the distribution of compounded GLP-1 medications.
These legal and regulatory developments highlight the complexities surrounding the use of GLP-1 drugs, both in their original and compounded forms, and underscore the importance of patient awareness regarding potential side effects and the legal status of the medications they use.
Victims of a data breach at Conduent Business Services LLC on Friday asked a New Jersey federal judge to greenlight an $80 million settlement resolving their claims that the company failed to adequately protect sensitive personal and health information of about 62 million people.
The Second Circuit on Friday denied a bid by Tylenol maker Kenvue and several retailers to reconsider its ruling that a district court improperly excluded expert testimony for plaintiffs who claim prenatal exposure to the over-the-counter pain reliever causes autism and ADHD.
The Second Circuit on Friday denied a bid by Tylenol maker Kenvue and several retailers to reconsider its ruling that a district court improperly excluded expert testimony for plaintiffs who claim prenatal exposure to the over-the-counter pain reliever causes autism and ADHD.
A pediatric health network and its information technology manager have agreed to pay $2.7 million to resolve the New York and Connecticut attorneys general's claims that they failed to institute "common" security measures to protect the personal data of patients impacted by a 2024 data breach, the states announced Friday.
Victims of a data breach at Conduent Business Services LLC on Friday asked a New Jersey federal judge to greenlight an $80 million settlement resolving their claims that the company failed to adequately protect sensitive personal and health information of about 62 million people.
The Second Circuit on Friday denied a bid by Tylenol maker Kenvue and several retailers to reconsider its ruling that a district court improperly excluded expert testimony for plaintiffs who claim prenatal exposure to the over-the-counter pain reliever causes autism and ADHD.
The Second Circuit on Friday denied a bid by Tylenol maker Kenvue and several retailers to reconsider its ruling that a district court improperly excluded expert testimony for plaintiffs who claim prenatal exposure to the over-the-counter pain reliever causes autism and ADHD.
A pediatric health network and its information technology manager have agreed to pay $2.7 million to resolve the New York and Connecticut attorneys general's claims that they failed to institute "common" security measures to protect the personal data of patients impacted by a 2024 data breach, the states announced Friday.